Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai, Maharashtra, India. It is one of the largest generic pharmaceutical companies by revenue globally.[10] The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.
History and evolution[edit]
Lupin was founded in 1968 by Desh Bandhu Gupta, who was a professor of chemistry at BITS-Pilani, Rajasthan. Gupta moved to Mumbai in the 60s to work on his business enterprise for which initially he had initially borrowed Rs 5000 from his wife to fund his venture. Subsequent funding from Central Bank of India, the company was able to start their manufacturing facility for producing folic acid and iron tablets for Government of India mother and child health program. Later Lupin started manufacturing anti TB drugs which at one point formed 36% of the company sales and was considered as the largest TB drugs manufacturer in the world.
After success with Lupin, in 1988 Gupta founded the group's CSR arm, the Lupin Human Welfare & Research Foundation (LHWRF). This initiative was dedicated to sustainable rural development with the aim to uplift families living below the poverty line.
As the company grew, in July 2015 the company announced its intention to acquire Gavis Pharmaceuticals and Novel Laboratories for $880 million.
The founder, Desh Bandhu Gupta died in June 2017 and was subsequently replaced as chairman by his wife, Manju Deshbandhu Gupta.
In October 2019, Pharma major lupin limited announced today the Appointment of Sreeji Gopinatham as Chief Information Officer (CIO).
In March 2019, the US FDA put several Lupin drug plants on notice for quality problems, and indicated it might not approve future Lupin drug applications.
Research and development
Lupin's research program covers the entire pharma product chain. The company's R&D program is headquartered in the Lupin Research Park located near Pune that houses over 1400 scientists. Lupin's R&D covers:
Businesses
Lupin's businesses encompass the entire pharmaceutical value chain, ranging from branded and generic formulations, APIs, advanced drug delivery systems to biotechnology. The company's drugs reach 70 countries with a footprint that covers advanced markets such as USA, Europe, Japan, Australia as well as emerging markets including India, the Philippines and South Africa to name a few.
USA
Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals Inc. (LPI), the company's US subsidiary is a $891 million enterprise. It has a presence in the branded and generics markets of the US. In the branded business, Lupin operates in the CVS and Pediatric segments. The company is the market leader in 28 products out of the 77 products marketed in the US generics market, of which it is amongst the Top 3 by market share in 57 of these products (IMS Health, December 2014): Suprax (Cefixime), a paediatric antibiotic, is Lupin's top-selling product here. Other products in Lupin's branded portfolio include Antara< (Fenofibrate), Locoid lotion, Alinia (Nitazoxanide) and InspiraChambers (Anti-static valved holding chamber). The company is also the 5th largest and fastest growing generics player in the US (5.3% market share by prescriptions, IMS Health). Lupin's US brands business contributed 9% of total US sales whereas the generics business contributed 91% during FY 2014–15.
India Region Formulations (IRF)
Lupin's IRF business focuses on Lifestyle diseases and Chronic disease therapy segments, particularly in Cardiology, Central Nervous System (CNS), Diabetology, Anti-Asthma, Anti-Infective, Gastro Intestinal and Oncology. The IRF business contributed 24% of the company's overall revenues for FY 2014–15, growing by 20% and recording revenues of ₹29,676 million (US$420 million) for FY 2014-15 as compared to ₹24,794 million (US$350 million) for FY 2013–14.
It has 12 manufacturing plants and 2 Research plants in India, as Jammu(J&K), Mandideep & Indore (Madhya pradesh), Ankaleswar & Dabasa (Gujarat), Tarapur, Aurangabad and Nagpur (Maharashtra), Goa, Visakhapatnam (Andhra Pradesh) and Sikkim; where research centre at Pune and Aurangabad. Among these the baby plant is Nagpur plant which will the biggest formulation unit for Lupin in coming year.
Europe
Lupin's focus in the European Union encompasses Anti-Infectives, Cardiovascular, and CNS therapy areas, along with niche opportunities in segments like Oral Contraceptives, Dermatology and Ophthalmics. The company's presence in France is by way of a trade partnership; in Germany, it operates through its acquired entity Hormosan Pharma GmbH. ] (Hormosan); while the UK business is a direct-to-market initiative.
Japan
Lupin is the fastest-growing Top 10 generic pharmaceuticals player in Japan (IMS). It operates in Japan through its subsidiary, Kyowa Pharmaceutical Industry Co. Ltd. (Kyowa), a company acquired in 2007, and I ’rom, Pharmaceutical Co. Ltd (IP), acquired in 2011. Kyowa has an active presence in Neurology, Cardiovascular, Gastroenterology and the Respiratory therapy segments. I'rom is a niche injectables company.
South Africa
Lupin's South African subsidiary, Pharma Dynamics (PD) is the fastest growing and the 4th largest generic company in the South African market (IMS). The company is a market leader in the Cardiovascular segment and has a growing presence in Neurology, Gastroenterology and the Over the Counter (OTC) segments.
No comments:
Post a Comment